Healthcare ❯ Pharmaceuticals

Gene Therapy

Clinical Trials Patient Safety Adverse Events Hemophilia Treatment Regulatory Approval Cost of Treatment Rare Diseases FDA Regulation Duchenne Muscular Dystrophy

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death

The hold follows a fatal capillary leak syndrome event prompting scrutiny of a newly introduced immune suppression agent